Trials / Completed
CompletedNCT02591732
A Nationwide Registry Study of Patients With Nonvalvular Atrial Fibrillation Initiating Oral Anticoagulation Therapies In The Early Period Following Apixaban Marketing In Denmark
A Nation-wide Registry Study of Patients With Non-valvular Atrial Fibrillation Initiating Anticoagulation Therapies in the Early Period Follow Apixaban Marketing in Denmark: Patient Characteristics, Treatment Patterns, and Early Bleeding Events
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 52,178 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to describe the characteristics of patients treated with different OATs and whether these characteristics differ between treatments. Furthermore to describe persistence to each OAT and risk of bleeding after initiating each OAT.
Conditions
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2015-06-01
- Completion
- 2015-06-01
- First posted
- 2015-10-30
- Last updated
- 2016-05-18
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT02591732. Inclusion in this directory is not an endorsement.